tbuckley/cabot-search huggingface dataset:
Chagas Disease After Organ Transplantation—United States, 2001
Journal: JAMA (2002)

Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi. Chagas disease following solid-organ transplantation has occurred in Latin America, where Chagas disease is endemic, but has not been reported previously in the United States. This report describes three cases in the United States of T cruzi infection associated with transplantation of organs from a single donor. CDC and the U.S. organ transplantation organizations will consider whether to recommend screening of potential donors for T cruzi infection and, if so, which donors to screen, how to screen, and what to do if the screening tests are positive.
A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
Authors: K Ikeda
Journal: Hepatology (1993)

To elucidate the appearance rates of hepatocellular carcinoma in cirrhosis and to assess the risk factors for hepatocellular carcinogenesis, we prospectively studied 795 consecutive patients with viral or alcoholic cirrhosis for 2 to 17 yr (median of 5.8 yr). During the observation period, hepatocellular carcinoma developed in 221 patients. Cumulative appearance rates of hepatocellular carcinoma were 19.4%, 44.3% and 58.2% at the end of the fifth, tenth and fifteenth years, respectively. When classified by the type of hepatitis virus infection, the appearance rates of hepatocellular carcinoma in 180 patients with only HBsAg and in 349 patients with only antibodies to hepatitis C virus were 14.2% and 21.5% at the fifth yr, 27.2% and 53.2% at the tenth yr and 27.2% and 75.2% at the fifteenth yr, respectively. Cox proportional hazard model identified that α-fetoprotein levels (p = 0.00001), age (p = 0.00067), positive hepatitis C virus antibodies (p = 0.00135), total alcohol intake (p = 0.00455) and indocyanine green retention rate (p = 0.04491) were independently associated with the appearance rates of hepatocellular carcinoma. Whereas age and indocyanine green retention rate were independent predictors for the appearance rate of liver tumor in the subgroup of HBsAg-positive patients, α-fetoprotein levels, age and past alcohol consumption were independent predictors in the group of hepatitis C virus antibody–positive patients. These epidemiological results suggest that some differences exist in the activity and modes of cancer promotion between hepatitis B virus infection and hepatitis C virus infection. (HEPATOLOGY 1993;18:47–53).
China's health reform: 10 years on
Authors: None The Lancet Public Health
Journal: The Lancet Public Health (2019)

In October, 2009, the Chinese Government launched Healthy China 2020—a political commitment to establishing an accessible, affordable, and efficient health system for all by 2020. The programme was later reinforced and expanded, in 2016, with Healthy China 2030, which incorporated the newly agreed Sustainable Development Goals (SDGs) and propelled Healthy China reform into the SDGs era. On July 15, 2019, the State Council announced a series of 15 recommended actions to achieve Healthy China, focusing on public health and prevention.
2018 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Summary
Authors: Jasmeet Soar, Michael W. Donnino, Ian Maconochie, Richard Aickin, Dianne L. Atkins, Lars W. Andersen, Katherine M. Berg, Robert Bingham, Bernd W. Böttiger, Clifton W. Callaway, Keith Couper, Thomaz Bittencourt Couto, Allan R. de Caen, Charles D. Deakin, Ian R. Drennan, Anne-Marie Guerguerian, Eric J. Lavonas, Peter A. Meaney, Vinay M. Nadkarni, Robert W. Neumar, Kee-Chong Ng, Tonia C. Nicholson, Gabrielle A. Nuthall, Shinichiro Ohshimo, Brian J. O’Neil, Gene Yong-Kwang Ong, Edison F. Paiva, Michael J. Parr, Amelia G. Reis, Joshua C. Reynolds, Giuseppe Ristagno, Claudio Sandroni, Stephen M. Schexnayder, Barnaby R. Scholefield, Naoki Shimizu, Janice A. Tijssen, Patrick Van de Voorde, Tzong-Luen Wang, Michelle Welsford, Mary Fran Hazinski, Jerry P. Nolan, Peter T. Morley
Journal: Circulation (2018)

The International Liaison Committee on Resuscitation has initiated a continuous review of new, peer-reviewed, published cardiopulmonary resuscitation science. This is the second annual summary of International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations that includes the most recent cardiopulmonary resuscitation science reviewed by the International Liaison Committee on Resuscitation. This summary addresses the role of antiarrhythmic drugs in adults and children and includes the Advanced Life Support Task Force and Pediatric Task Force consensus statements, which summarize the most recent published evidence and an assessment of the quality of the evidence based on Grading of Recommendations, Assessment, Development, and Evaluation criteria. The statements include consensus treatment recommendations approved by members of the relevant task forces. Insights into the deliberations of each task force are provided in the Values and Preferences and Task Force Insights sections. Finally, the task force members have listed the top knowledge gaps for further research.
Cancer, Philadelphia
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: “Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells”
Authors: Danqi Chen, Lei Fang, Shenglin Mei, Hongjie Li, Xia Xu, Thomas L. Des Marais, Kun Lu, X. Shirley Liu, Chunyuan Jin
Journal: Environmental Health Perspectives (2018)

[This corrects the article DOI: 10.1289/EHP1275.].
Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014
Authors: Eliezer M. Van Allen, Levi A. Garraway, Jonathan E. Rosenberg
Journal: European Urology (2015)
The Oesophagus
Authors: Arthur E. Baue
Journal: JAMA (1964)

With a crisp, definitive style, Mr. Flavell provides considerable coverage of esophageal disease and its surgical management in a brief account which does not attempt to be encyclopedic. He limits himself to descriptions of techniques which he has found satisfactory in his unit at the London Hospital but does cite most of the important literature on esophageal surgery. The approaches presented are sound and many practical suggestions are given which are helpful. Problem areas are emphasized. Since it is a personal account, more of his own results would have been interesting. Because of brevity, the reader may have difficulty in recognizing personal preferences or opinions as such. This occurs in several places with statements such as, "Passage of the esophagoscope is best carried out under general anesthesia," and "Esophagoscopy is indicated in achalasia only when the diagnosis is in doubt...." Such assertions are no problem for the thoracic surgeon but
THE INDEX MEDICUS NOVUS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early diagnosis of acute myocardial infarction.
Journal: BMJ (1991)

REPLY,-My article made clear that single enzyme measurements are rarely diagnostic in the first 12 hours.Serial measurements are more useful, but in the real world of a busy hospital and an understaffed biochemistry laboratory this is unlikely to find much favour, particularly when the method requires four hourly blood sampling and construction of a "log creatine kinase slope."Even if the method were practicable it would not permit diagnosis until 12 hours or more after admission (perhaps 16 hours after infarction), when the benefits of thrombolytic treatment are considerably diminished and when electrocardiography often shows unequivocal changes.Practical considerations aside, I am less enthusiastic than Dr Mullen about the validity of this method.The main differential diagnosis in patients with cardiac chest pain is between unstable angina and acute infarction.Difficulties arise only if the electrocardiogram taken on ad- mission to hospital is non-diagnostic, and an additional test may be required.Collinson et al gave no information about admission electro- cardiograms, and in the 1989 study only one patient had unstable angina compared with 34 with acute infarction-which makes it difficult to assess the test's discriminatory value.Indeed, they seem to acknowledge this difficulty by diagnosing five patients as "ischaemia ?infarction," a conundrum
An Overview of Emergency Medical Care Services
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction
Journal: New England Journal of Medicine (1981)

A multicenter double-blind randomized study was carried out to compare the effect of timolol (10 mg twice daily) with that of placebo in patients surviving acute myocardial infarction. Treatment was started seven to 28 days after infarction in 1884 patients (945 taking timolol, and 939 placebo), who represented 52 per cent of those evaluated for entry; the patients were followed for 12 to 33 months (mean, 17). There were 152 deaths in the placebo group and 98 in the timolol group. When deaths that occurred during treatment or within 28 days of withdrawal were considered, the cumulated sudden-death rate over 33 months was 13.9 per cent in the placebo group and 7.7 per cent in the timolol group--a reduction of 44.6 per cent (P = 0.0001). The cumulated reinfarction rate was 20.1 per cent in the placebo group and 14.4 per cent in the timolol group (P = 0.0006). We conclude that long-term treatment with timolol in patients surviving acute myocardial infarction reduces mortality and the rate of reinfarction.
Transactions of the Medical Association of Georgia.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA (2015)

Treatment of Patients Co-infected With Hepatitis C and HIV 1223Treatment of patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) is challenging.In a randomized, open-label study that included 63 patients with HCV genotype 1 and HIV co-infection and who were either treatment-naive or did not respond to prior treatment with pegylated interferon plus ribavirin, Sulkowski and colleagues found that 12 or 24 weeks' treatment with an all-oral, interferon-free antiviral regimen consisting of ombitasvir/paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin resulted in high sustained virologic response rates.In an Editorial, Graham discusses treatment of patients co-infected with HCV and HIV.
Pigmentation of Serum in Rheumatoid Arthritis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
Authors: Kyle E. Rusthoven, Brian D. Kavanagh, Higinia Cardenes, Volker W. Stieber, Stuart H. Burri, Steven J. Feigenberg, Mark A. Chidel, Thomas J. Pugh, Wilbur Franklin, Madeleine Kane, Laurie E. Gaspar, Tracey E. Schefter
Journal: Journal of Clinical Oncology (2009)

To evaluate the efficacy and tolerability of high-dose stereotactic body radiation therapy (SBRT) for the treatment of patients with one to three hepatic metastases. Patients with one to three hepatic lesions and maximum individual tumor diameters less than 6 cm were enrolled and treated on a multi-institutional, phase I/II clinical trial in which they received SBRT delivered in three fractions. During phase I, the total dose was safely escalated from 36 Gy to 60 Gy. The phase II dose was 60 Gy. The primary end point was local control. Lesions with at least 6 months of radiographic follow-up were considered assessable for local control. Secondary end points were toxicity and survival. Forty-seven patients with 63 lesions were treated with SBRT. Among them, 69% had received at least one prior systemic therapy regimen for metastatic disease (range, 0 to 5 regimens), and 45% had extrahepatic disease at study entry. Only one patient experienced grade 3 or higher toxicity (2%). Forty-nine discrete lesions were assessable for local control. Median follow-up for assessable lesions was 16 months (range, 6 to 54 months). The median maximal tumor diameter was 2.7 cm (range, 0.4 to 5.8 cm). Local progression occurred in only three lesions at a median of 7.5 months (range, 7 to 13 months) after SBRT. Actuarial in-field local control rates at one and two years after SBRT were 95% and 92%, respectively. Among lesions with maximal diameter of 3 cm or less, 2-year local control was 100%. Median survival was 20.5 months. This multi-institutional, phase I/II trial demonstrates that high-dose liver SBRT is safe and effective for the treatment of patients with one to three hepatic metastases.
Table of Contents
Authors: Moira Lewitt, Kerstin Hall, Peter Bang, Kerstin Brismar, Minoru Inoue, Eisuke Maehata, Masao Yano, Matsuo Taniyama, Seiji Suzuki, Kirsten Schultz, Lars Rasmussen, Thomas Ledet, Takeo Ogawa, Hiroshi Hirose, Kiichi Miyashita, Ikuo Saito, Takao Saruta, Elisa Maria, Sousa Russo-Carbolante, Ana Caleiro, Seixas Azzolini, Ana Christina, Morseli Polizello, Ana De Assis-Pandochi, Yara Lucisano-Valim, Raffaele Napoli, Domenico Cozzolino, Vincenzo Guardasole, Valentina Angelini, Emanuela Zarra, Margherita Matarazzo, Antonio Cittadini, Luigi Saccà, Roberto Torella
Journal: Metabolism (2005)
Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy
Authors: U. Pastorino, M. Silva, S. Sestini, F. Sabia, M. Boeri, A. Cantarutti, N. Sverzellati, G. Sozzi, G. Corrao, A. Marchianò
Journal: Annals of Oncology (2019)

Ann Oncol 2019; (doi:10.1093/annonc/mdz117) In the original article, the Figure 1 caption contained an erroneous sentence. It has now been corrected to read: ‘Cumulative overall mortality and lung cancer mortality, by arm over 10 years of follow-up.’ The Publisher apologizes for the error. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacyAnnals of OncologyVol. 30Issue 7PreviewThe National Lung Screening Trial showed that lung cancer (LC) screening by three annual rounds of low-dose computed tomography (LDCT) reduces LC mortality. We evaluated the benefit of prolonged LDCT screening beyond 5 years, and its impact on overall and LC specific mortality at 10 years. Full-Text PDF Open Access
THE CLINICAL VALUE OF RECENT ADVANCES IN GASTRIC ANALYSIS
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Food and Drug Administration
Authors: Stuart L. Nightingale
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal